PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Trial details
- Registry ID
- NCT01155362
- Drugs studied
- Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
TrialRedline tracks 2 clinical trials sponsored by Celularity Incorporated: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's DiseaseNCT01155362 | Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control | Completed | 2012-02Actual |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.NCT02264288 | PDA-002 | Terminated | 2018-02-27Actual |
Names as written in the registry records.
NCT01155362 · Celularity Incorporated
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: A reduction from baseline by 25% and/or > 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).. After: Measure: Percentage of Subjects With Clinical Response Based on Crohn's Disease Activity Index (CDAI) at Both Week 4 and Week 6.
NCT02264288 · Celularity Incorporated
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Complete wound closure of the index ulcer Measure: Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations. After: Measure: Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 Months.
Before: 28 Feb 2018. After: 27 Feb 2018.